All In Biotech

Drug Trial Radar · NCT05604885

A Dose-range Study of the Safety and Efficacy of Treatment in Adult Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate

A Two-part, Randomized, Double-blind, Multi-center, Placebo-controlled Study of the Dose-range, Safety and Efficacy of 4 and 12 Weeks of Treatment With AP1189 in Adult Rheumatoid Arthritis (RA) Patients With an Inadequate Response to Methotrexate (MTX) Alone - (RESOLVE)

Last checked: Nov 19, 2026Latest source record: Nov 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 125 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

125

Actual

Start

Nov 30, 2022

Primary completion

Aug 28, 2023

Study completion Aug 28, 2023

Sponsor

Lead sponsor
SynAct Pharma ApsIndustry
Sponsor type
Industry
Collaborators
NBCD A/S
First posted
Nov 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The RESOLVE study is a two-part, randomized, double-blind, multi-center, placebo-controlled study of the safety, dose-range finding confirmation, and efficacy of 4 (Part A) and 12 weeks (Part B) of treatment with AP1189 in adult RA patients with an inadequate response to MTX alone.

Conditions

  • Rheumatoid Arthritis

Interventions

  • AP1189, 60 mgDrug

    AP1189 tablets for oral use

  • AP1189, 80 mgDrug

    AP1189 tablets for oral use

  • AP1189, 100 mgDrug

    AP1189 tablets for oral use

  • PlaceboDrug

    Matching placebo tablets for oral use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Change in ACR20Time frame: 4 weeks
  2. Part B: Change in ACR20Time frame: 12 weeks
  3. Number of reported Adverse EventsTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Timofei Mosneaga Republican Clinical Hospital

    Chisinau, Moldova

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.